 EL SEGUNDO, Calif.--BUSINESS WIRE--NantKwest, Inc. NASDAQ: NK, a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ISS, Glass, Lewis Co., LLC Glass Lewis, and Egan-Jones Proxy Services Egan-Jones have recommended NantKwest stockholders vote FOR the pending merger with ImmunityBio. ISS concluded in its February 24, 2021 report: Both NK and ImmunityBio have 